Follow us

Contributed By:

Jessica Kittams

OHSU Researcher Criticizes Drug Prices

OPB | April 29, 2013 12:35 p.m. | Updated: Sept. 11, 2013 12:45 a.m.

Brian Druker, director of the Knight Cancer Institute at OHSU, is critical of pharmaceutical companies’ profit margins. He co-authored a newly published letter in a the medical journal Blood criticizing the expense of a drug he helped develop. That drug, Gleevec, is now used by over 200,000 cancer patients worldwide, and can cost up to $100,000 a year. Dr. Druker hopes to begin working with lawmakers to change the way pharmaceutical companies price their drugs.

Have you or a loved one been through cancer treatment? What were the financial barriers to your treatment? Would you support governmental regulating pharmaceutical pricing?


blog comments powered by Disqus
Thanks to our Sponsors:
become a sponsor


Thanks to our Sponsors
become a sponsor

Funding Provided By

Rose E. Tucker Charitable Trust

James F. and Marion L. Miller Foundation

Dawn and Al Vermeulen

Ray and Marilyn Johnson